Patents Assigned to Medical Research & Development Fund for Health Ser vices Bnai Zion Medical Center
  • SEMAPHORIN 3A FOR TREATMENT AND PROGNOSIS OF SYSTEMIC LUPUS ERYTHEMATOSUS
    Publication number: 20160129079
    Abstract: The subject matter relates to Semaphorin 3A (Sema3A) and its use in treatment and prognosis of Systemic Lupus Erythematosus (SLE). Provided are, inter-alia, methods of treating a subject afflicted with SLE, comprising administering to the subject a pharmaceutical composition comprising isolated Sema3A. Further provided are methods for prognosis of SLE, comprising measuring Sema3A serum concentration in a subject in need thereof.
    Type: Application
    Filed: June 13, 2013
    Publication date: May 12, 2016
    Applicant: Medical Research & Development Fund for Health Ser vices Bnai Zion Medical Center
    Inventors: Zahava VADASZ, Elias TOUBI